A February 2020 article published by the JAMA medical journal, “Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia — Two Randomized Clinical Trials”, reports on the rate of hypophosphatemia associated with Injectafer compared to another intravenous iron deficiency anemia drug called Monoferric. This new Injectafer drug safety information concerning patients who develop hypophosphatemia following Injectafer treatments. when summarized as follows, is rather alerting:
- The hypophosphatemia incidence rate with Injectafer was 75% compared to 7.9% for Monoferric in the first trial; and,
- The hypophosphatemia incidence rate with Injectafer was 73.7% compared to 8.1 % for Monoferric in the second trial.
If a patient getting an Injectafer treatment develops Severe Hypophosphatemia (Severe HPP) they might thereafter be diagnosed with one of the following medical complications:
- Cardiac Arrest
- Respiratory Failure
In this earlier post on our Drug Injury Watch blog, “Injectafer-Induced Hypophosphatemia Can Be A Serious Side Effect Of This Iron Deficiency Anemia Drug”, we considered how Injectafer (ferric carboxymaltose) can cause hypophosphatemia (HPP) as a side effect.
We are investigating possible drug injury lawsuits for patients who develop hypophosphatemia associated with Injectafer, i.e., hypophosphatemia following Injectafer treatments, and thereafter are diagnosed with a related medical complication.[View article at original source]